Who We Are
We are focused on disrupting heart valve disease and restoring healthy heart function. Our team focuses on tackling clinical gaps and redefining positive outcomes by developing solutions designed to mimic the heart’s native physiology.
1. Kodali SK, Sorajja P, Meduri CU, et al. Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve - DurAVR. EuroIntervention. 2023;19(4):e352-e362. Published 2023 Jul 17. doi:10.4244/EIJ-D-23-00282.
News, Presentations and Interviews
News, Presentations and Interviews
The recording of our Annual General Meeting is now available for viewing. This comprehensive session includes detailed discussions, strategic updates, and future plans that underscore the continued growth and innovation at Anteris Technologies.
Watch leading experts in the field of TAVR discuss the biomimetic design of the DurAVR® THV and its impact on hemodynamics and blood flow dynamics, presented by Drs. Christopher Meduri, Susheel Kodali, João Cavalcante, Michael Reardon, Nicolas Van Mieghem, Azeem Latib, Anita Asgar and Vinayak Bapat.
Key takeaways included:
We are excited to share the promising results from a valve-in-valve (ViV) study led by Dr. Anita Asgar and recently presented at New York Valves. The data demonstrated restoration of hemodynamic performance in five complex cases in which patients underwent a DurAVR® Transcatheter Heart Valve implantation after their surgical replacement valves failed.
Dr. Asgar emphasized, “This data set of valve-in-valve patients highlights the impact of the DurAVR® valve biomimetic design by restoring these patients’ hemodynamics to the performance of their initial surgical valve and is very encouraging for the wave of valve-in-valve patients that are coming in the future.”
We are pleased to announce new DurAVR® THV First-in-Human study data was presented at New York Valves by imaging expert Dr. João Cavalcante. “When we look at commercially available surgical or TAVR valves, we are still seeing abnormal flow patterns on cardiac MRI. The restoration of laminar flow, as we are seeing with this new DurAVR® THV, is a byproduct of the intrinsic valve design and novel technology, which might have positive downstream implications to the arteries and consequently to ventricle, and ultimately to the patients,” stated Dr. Cavalcante.
The recording of our Annual General Meeting is now available for viewing. This comprehensive session includes detailed discussions, strategic updates, and future plans that underscore the continued growth and innovation at Anteris Technologies.
We invite all stakeholders, partners, and interested parties to watch this recording to stay informed about our latest developments and achievements. Your continued support and engagement are greatly appreciated.
In this video, Drs Nicolas Van Mieghem, Christopher Meduri, and Azeem Latib discuss the biomimetic design of the DurAVR® transcatheter heart valve (THV) and its impact on hemodynamics and blood flow dynamics. Learn about:
At SCAI 2024, Dr Azeem Latib presented an update on the DurAVR® THV First-in-Human Study, including consistent hemodynamics and excellent safety profile through 1-year post-implantation.
Learn about:
At CRT 2024, Dr Rishi Puri presented an update on DurAVR® THV. The biomimetic valve is showing consistently promising hemodynamic performance—measured by EOA, MPG, and DVI—from 30 days through 1 year. Learn about DurAVR® THV and view the full presentation on the EFS and FIH studies below.
At CRT 2024, Dr Thomas Waggoner presented 30-day data from the DurAVR® transcatheter heart valve (THV) Early Feasibility Study (EFS). The data substantiates the promising hemodynamic (blood flow) results reported to date with the DurAVR® THV, a new class of biomimetic THV designed to restore normal blood flow in aortic stenosis. The latest data includes 30-day results for all 28 patients treated in the First-In-Human Study (Cohorts 1-4) in addition to 30-day results for all 15 patients treated in the US Early Feasibility Study. View the full presentation below.
In this expert interview from PCR London Valves 2023, Dr Vinayak Bapat interviews Dr Anita Asgar regarding the challenges physicians face today with valve-in-valve (ViV) patients and the potential utility of DurAVR® for ViV procedures through case-based discussion. Learn about:
Watch this physician panel and hear Drs Michael Reardon, Christopher Meduri, and Azeem Latib discuss the design of the DurAVR® Transcatheter Heart Valve and the paradigm-shifting hemodynamic results from the Early Feasibility Study (EFS).
Learn about:
View the latest investor-related updates
